The pharmaceutical retail industry presents a paradox: it is highly regulated yet fragmented. This dichotomy arises from the diverse range of stakeholders, each with their own interests and priorities. This fragmentation poses challenges for medical and more retailers in complying with regulations, tracking inventory, and preventing counterfeit products from infiltrating the supply chain.
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of...
Immunotherapy treatments such as checkpoint-inhibiting drugs have radically improved the treatment paradigm for a range of cancers, with one notable exception: prostate tumors, which are considered “cold,” or resistant to an immune attack. Now, a team helmed by the University of Michigan Rogel Cancer Center has found a protein target that it believes could make prostate tumors amenable to immunotherapy—and a drug candidate to target it.
NEWARK, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTC PINK: ARDM) (“Aradigm” or the “Company”) announced on April 27, 2020, the Bankruptcy Court entered an order (i) conditionally approving the disclosure statement for the Combined Chapter 11 Plan and Disclosure Statement (the “Combined Plan”) filed by Aradigm Corporation (the “Company”); (ii) directing the Company to distribute the Combined Plan to creditors and shareholders for voting; and (iii) fixing April 24, 2020 as the record date for shareholders and creditors to vote.